176 related articles for article (PubMed ID: 9365071)
1. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate).
Landsmeer-Beker EA; Massa GG; Maaswinkel-Mooy PD; van de Kamp JJ; Papapoulos SE
Eur J Pediatr; 1997 Oct; 156(10):792-4. PubMed ID: 9365071
[TBL] [Abstract][Full Text] [Related]
2. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
3. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.
Sakkers R; Kok D; Engelbert R; van Dongen A; Jansen M; Pruijs H; Verbout A; Schweitzer D; Uiterwaal C
Lancet; 2004 May; 363(9419):1427-31. PubMed ID: 15121405
[TBL] [Abstract][Full Text] [Related]
4. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
6. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
[TBL] [Abstract][Full Text] [Related]
7. Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment.
Trejo P; Fassier F; Glorieux FH; Rauch F
J Bone Miner Res; 2017 May; 32(5):1034-1039. PubMed ID: 28019684
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial.
Kok DH; Sakkers RJ; Janse AJ; Pruijs HE; Verbout AJ; Castelein RM; Engelbert RH
Eur J Pediatr; 2007 Nov; 166(11):1155-61. PubMed ID: 17308899
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
Feehan AG; Zacharin MR; Lim AS; Simm PJ
Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
[TBL] [Abstract][Full Text] [Related]
12. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
Zeitlin L; Rauch F; Plotkin H; Glorieux FH
Pediatrics; 2003 May; 111(5 Pt 1):1030-6. PubMed ID: 12728084
[TBL] [Abstract][Full Text] [Related]
13. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
14. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
15. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
[TBL] [Abstract][Full Text] [Related]
16. Interventions for Improving Bone Mineral Density and Reducing Fracture Risk in Osteogenesis Imperfecta: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials.
Sridharan K; Sivaramakrishnan G
Curr Clin Pharmacol; 2018; 13(3):190-198. PubMed ID: 30160216
[TBL] [Abstract][Full Text] [Related]
17. The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta.
Biggin A; Zheng L; Briody JN; Coorey CP; Munns CF
Horm Res Paediatr; 2015; 83(3):183-9. PubMed ID: 25676713
[TBL] [Abstract][Full Text] [Related]
18. Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta.
Lin CH; Chien YH; Peng SF; Tsai WY; Tung YC; Lee CT; Chien CC; Hwu WL; Lee NC
Pediatr Neonatol; 2014 Aug; 55(4):306-11. PubMed ID: 24486247
[TBL] [Abstract][Full Text] [Related]
19. Osteogenesis Imperfecta: Skeletal Outcomes After Bisphosphonate Discontinuation at Final Height.
Robinson ME; Trejo P; Palomo T; Glorieux FH; Rauch F
J Bone Miner Res; 2019 Dec; 34(12):2198-2204. PubMed ID: 31356699
[TBL] [Abstract][Full Text] [Related]
20. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]